Springer Amends 13D Filing for Cartesian Therapeutics

TL;DR

Springer updated his 13D filing for Cartesian Therapeutics. Watch for ownership changes.

AI Summary

Timothy A. Springer filed an amendment (No. 13) to Schedule 13D on April 12, 2024, regarding Cartesian Therapeutics, Inc. The filing indicates a change in beneficial ownership of the company's common stock. The specific details of the change in ownership percentage or number of shares are not explicitly stated in this excerpt, but it is an update to a previous filing.

Why It Matters

This amendment signals a potential shift in significant ownership stakes, which could influence the company's stock price and strategic direction.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D often indicate significant changes in beneficial ownership, which can lead to increased stock volatility.

Key Numbers

• 13 — Amendment Number (This is the 13th amendment to the Schedule 13D filing.)
• 20240412 — Filing Date (The amendment was filed on April 12, 2024.)

Key Players & Entities

• Timothy A. Springer (person) — Filing person
• Cartesian Therapeutics, Inc. (company) — Subject company
• Michael K. Bradshaw, Jr. (person) — Authorized to receive notices
• Nelson Mullins Riley & Scarborough LLP (company) — Legal counsel

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o

Filing Documents

• ea0203800-13da13spring_cart.htm (SC 13D/A) — 65KB
• 0001213900-24-032571.txt ( ) — 66KB

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration .

of the Schedule 13D is hereby amended to be supplemented by

Item 3 of the Schedule 13D is hereby amended to be supplemented by the following: On March 27, 2024, the Issuer held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the stockholders of the Issuer approved a 1-for-30 reverse stock split (the “Reverse Stock Split”) of the Common Stock and the conversion of the Series A Preferred Stock into shares of Common Stock. The Reverse Stock Split as effected on April 4, 2024. The amount of securities reported in this Amendment No. 13 reflect the Reverse Stock Split. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the “Automatic Conversion”). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the Issuer’s filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the Reporting Persons’ shares of Series A Preferred Stock converted into shares of Common Stock. CUSIP No . 816212104 13D Page 6 of 7 Pages

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer .

of Schedule 13D is hereby amended and restated in full as follows

Item 5 of Schedule 13D is hereby amended and restated in full as follows: The information set forth under Item 3 and the cover page of the Schedule 13D is incorporated herein by reference into this Item 5. (a) The percentages of beneficial ownership reported in this Item 5, and on each Reporting Person’s cover page to this Statement, are based on a total of 17,779,787 Shares issued and outstanding as of April 8, 2024, as reported on the Issuer’s Current Report on Form 8-K, dated April 9, 2024. All of the Share numbers reported below, and on each Reporting Person’s cover page to this Statement, are as of April 8, 2024. The Reporting Persons, in the aggregate, beneficially own 6,473,184 Shares, representing approximately 36.4% of such class of securities. Dr. Springer is the beneficial owner of a total of 6,473,184 Shares, representing approximately 36.4% of the outstanding Shares and consisting of (i) 4,373,966 Shares held directly, (ii) 1,055 Shares issuable upon exercise of outstanding options exercisable within 60 days of April 8, 2024, (iii) 1,927,630 Shares held by TAS, (iv) 167,040 Shares underlying warrants exercisable within 60 days of April 8, 2024 held by TAS, and (v) 3,493 Shares held by Dr. Lu. TAS is the beneficial owner of a total of 2,094,670 Shares, representing approximately 11.8% of the outstanding Shares and consisting of (i) 1,927,630 Shares and (ii) 167,040 Shares underlying warrants exercisable within 60 days of April 8, 2024. TAS holds all such Shares directly. Dr. Springer is the sole managing member of TAS. Dr. Lu is the beneficial owner of a total of 3,493 Shares, representing approximately 0.0% of the outstanding Shares. Dr. Lu holds all such Shares directly. Dr. Lu is the spouse of Dr. Springer. (b) Dr. Springer exercises sole voting and dispositive power over the Shares held by him directly and the Shares held by TAS. Dr. Springer disclaims beneficial ownership of the Shares held by TAS, except to the extent of hi

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: April 12, 2024 /s/ Timothy A. Springer Timothy A. Springer /s/ Chafen Lu Chafen Lu TAS Partners LLC By: /s/ Timothy A. Springer Name: Timothy A. Springer Title: Manager

View Full Filing

View this SC 13D/A filing on SEC EDGAR